Crossmark

Anti-DEspR antibody treatment improves survival and reduces neurologic deficits in a hypertensive, spontaneous intracerebral hemorrhage (hsICH) rat model

Crossref DOI link: https://doi.org/10.1038/s41598-023-28149-3

Published Online: 2023-02-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Herrera, Victoria L. M.

Gromisch, Christopher M.

Decano, Julius L.

Pasion, Khristine Amber

Tan, Glaiza L. A.

Hua, Ning

Takahashi, Courtney E.

Greer, David M.

Ruiz-Opazo, Nelson
Funding

Funding for this research was provided by:

Ellison Foundation, United States
License Information

Text and Data Mining valid from 2023-02-15

Version of Record valid from 2023-02-15
More Information

Article History

Received: 3 April 2022

Accepted: 13 January 2023

First Online: 15 February 2023

Competing interests

: VLMH and NRO: co-inventors on BU patents on DEspR and DEspR-inhibition for stroke therapy. All other authors have no competing interests.

Document is current

Any future updates will be listed below